HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG), ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of ...
HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
In preclinical burn models, treatment with proprietary fibroblast spheroids (CYWC628) was associated with nearly a four-fold increase in tissue-level IL-10, a cytokine known to support tissue repair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results